Findings

What do systematic reviews say?

146 questions · 147 findings · 48 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 4.1%GRADE not reported 6 · 4.1%Very low 10 · 6.8%Low 33 · 22.4%Moderate 53 · 36.1%High 39 · 26.5%

Intervention not reported

Mortality (calculated instead of overall survival)

The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).

1 finding from 1 review

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
HR 0.48 [0.22, 1.06]
5 studies · 1388 participants
Moderate

Intervention not reported

Mortality (calculated instead of overall survival)

The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).

1 finding from 1 review

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
HR 2.12 [1.03, 4.37]
1 study · 276 participants
Low

Gemcitabine combinations vs gemcitabine

Overall survival ‐ Gemcitabine plus fluoropyrimidine · advanced pancreatic cancer

Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).

1 finding from 1 review

Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
HR 0.89 [0.81, 0.97]
10 studies · 2718 participants
High

Gemcitabine combinations vs gemcitabine

Overall survival ‐ Gemcitabine plus topoisomerase inhibitor · advanced pancreatic cancer

Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).

1 finding from 1 review

Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
HR 1.01 [0.87, 1.16]
3 studies · 839 participants
High

Concomitant (concurrent) chemoradiotherapy vs Radiotherapy alone

Overall survival, adjuvant concomitant chemoradiotherapy vs post-surgery radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Concomitant (concurrent) chemoradiotherapy probably leads to lower overall survival, concurrent chemoradiotherapy vs radiotherapy alone… compared with radiotherapy alone (non-resectable tumours) (moderate certainty).

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy 2021 · Cochrane All outcomes
HR 0.74 [0.67, 0.83]
24 studies · 2852 participants
Moderate

Intervention not reported

Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias

The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).

1 finding from 1 review

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
HR 0.31 [0.19, 0.52]
3 studies · 816 participants
Moderate